Dompé pursues ambitions with Anabasis buy
This article was originally published in Scrip
Executive Summary
Dompé farmaceutici's decision to acquire the 51% of Anabasis Pharma it does not already own is wholly consistent with its ambition to become a fully integrated international biotech company with a robust clinical pipeline. Starting in 2007, with an empty clinical pipeline and a vulnerable reliance on the Italian primary care market, the private Italian pharmaceutical company, has been reinventing itself as an international research-powered biopharmaceutical company.